GlassScriptPhysician profile
Amy J Ganske
NPI 1891891339
$3,489.78
in general payments reported to CMS, 2019-2025
37 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.28 · 2022: $426 · 2023: $700 · 2024: $833 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,099.04 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $940.02 | 2023-2025 | Phesgo, Perjeta, Itovebi |
| Merck Sharp & Dohme LLC | $268.16 | 2022-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $250.50 | 2022-2025 | Enhertu, Tagrisso |
| Daiichi Sankyo INC. | $209.96 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Janssen Biotech, INC. | $194.07 | 2023-2025 | Erleada, Darzalex, Tecvayli |
| Pfizer INC. | $192.80 | 2022-2024 | |
| Seagen INC. | $156.34 | 2022-2023 | Padcev, Tivdak |
| Novartis Pharmaceuticals Corporation | $136.66 | 2022-2025 | |
| Abbvie INC. | $127.66 | 2023-2025 | |
| Array Biopharma INC | $113.57 | 2022-2025 | Tukysa, Mektovi, Braftovi |
| Bayer Healthcare Pharmaceuticals INC. | $105.40 | 2025 | |
| Jazz Pharmaceuticals INC. | $98.86 | 2022-2023 | |
| Celgene Corporation | $80.42 | 2023-2025 | Reblozyl |
| Genzyme Corporation | $64.85 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.88 | 2023-2024 | Gammagard |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $54.81 | 2023-2024 | Cabometyx |
| Puma Biotechnology, INC. | $40.49 | 2021 | |
| Lilly USA, LLC | $33.68 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $29.73 | 2022 | |
| Janssen Scientific Affairs, LLC | $23.79 | 2021 | |
| Blueprint Medicines Corporation | $23.17 | 2024 | Ayvakit |
| Tersera Therapeutics LLC | $22.96 | 2024 | Xermelo |
| Pharmaessentia USA Corporation | $22.79 | 2023 | Besremi |
| Gilead Sciences, INC. | $21.12 | 2024 | |
| Servier Pharmaceuticals LLC | $20.55 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.03 | 2024 | Onivyde |
| Deciphera Pharmaceuticals INC. | $18.02 | 2025 | |
| Beigene USA, INC. | $17.63 | 2024 | Brukinsa |
| Incyte Corporation | $17.59 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $17.44 | 2023 | Opdivo |
| Tempus Ai, INC | $15.84 | 2024 | |
| Cti Biopharma Corp. | $15.42 | 2023 | Vonjo |
| Taiho Oncology, INC. | $15.39 | 2024 | |
| Beone Medicines USA, INC. | $14.71 | 2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $14.32 | 2024 | |
| Coherus Oncology, INC. | $14.21 | 2024 | |
| Novocure INC. | $13.94 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ganske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.